< Back to previous page
Researcher
Jeroen Dekervel
- Disciplines:Analysis of next-generation sequence data, Single-cell data analysis, Cancer diagnosis, Cancer therapy
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From1 Oct 2018 → Today - Hepatology (Division)
Member
From1 Oct 2012 → 2 Oct 2016
Projects
1 - 7 of 7
- Neoadjuvant therapy in the treatment of esophageal adenocarcinoma: one size doesn’t fit allFrom14 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in digestive tumorsFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation, refinement and spatial orientation of CD45RA effector-memory CD8 T-cells and PDL1- expressing CXCL10+ macrophages as predictive markers for response to immune checkpoint inhibition in advanced hepatocellular carcinoma.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- [18F]AlF-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors: comparison with [68Ga]Ga-DOTATATE and evaluation of routine clinical use.From3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Personalized multimodal treatment for resectable esophageal cancer by detecting minimal residual disease (MRD) using circulating tumor DNA (ctDNA):From11 Jan 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- SAFIR-ABC10: molecular screening for precision medicine in advanced biliary cancersFrom1 Jan 2022 → TodayFunding: Foundations, funds and other with scientific goal
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → 1 Oct 2023Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 58
- Gastrointestinal issue: Advances in gastrointestinal oncology.(2024)
Authors: Jeroen Dekervel
Pages: 102437 - Controversies in upper GI oncology: first-line systemic treatment in MASLD-associated HCC(2024)
Authors: Jeroen Dekervel
- Controversies in upper GI oncology: maintenance treatment in pancreatic cancer(2024)
Authors: Jeroen Dekervel
- Fulminant ectopic Cushing's syndrome caused by metastatic small intestine neuroendocrine tumour - a case report and review of the literature.(2024)
Authors: Jeroen Dekervel
Pages: 48 - 51 - PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma(2023)
Authors: Sarah Cappuyns, Bram Boeckx, Ingrid Arijs, Aurelie Mechels, Baki Topal, Chris Verslype, Diether Lambrechts, Jeroen Dekervel
- PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA(2023)
Authors: Jeroen Dekervel
Pages: S1871 - S1872 - The ongoing search for biomarkers of response to systemic therapy in advanced hepatocellular carcinoma.(2023)
Authors: Sarah Cappuyns, Jeroen Dekervel, Eric Van Cutsem, Chris Verslype, Diether Lambrechts
- Impact on clinical management when using [18F]AlFNOTA-octreotide instead of [68Ga]Ga-DOTA-SSA PET/CT in neuroendocrine tumor patients: preliminary results(2023)
Authors: Jeroen Dekervel, Frederik Cleeren, Michel Koole, Guy Bormans, Chris Verslype, Christophe Deroose
Pages: S508 - S508 - Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study(2023)
Authors: Chris Verslype, Tania Roskams, Sabine Tejpar, Isabelle Vanden Bempt, Jeroen Dekervel
Pages: 9173 - 9181 - Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus(2023)
Authors: Liselotte Fierens, Jeroen Dekervel, Els Wauters, João Guedelha Sabino
Pages: 36 - 57